Hormonal
Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.
Newer medications like Tirzepatide (a dual agonist) may offer greater weight loss and improvements in blood pressure and cholesterol than older GLP-1 drugs. However, long-term data on whether this translates to fewer heart attacks or strokes is still being collected. If standard GLP-1s are not achieving your metabolic goals, discuss these newer options with your doctor.
Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated.
Why this rating
Based on robust metabolic trial data (SURMOUNT, SURPASS) but limited or ongoing hard cardiovascular outcome data (SURPASS-CVOT).
Source
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Neerav Mullur et al. · Journal of Endocrinology · 2024
DOI 10.1530/joe-24-0046
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction, and stroke, in patients with type 2 diabetes and high cardiovascular risk.Strong
- Some GLP-1RAs (e.g., Lixisenatide, Exenatide, oral Semaglutide) show neutral cardiovascular outcomes in patients with Type 2 Diabetes, suggesting that not all GLP-1RAs provide cardiovascular protection.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →